<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477657</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 26813</org_study_id>
    <nct_id>NCT02477657</nct_id>
  </id_info>
  <brief_title>Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology</brief_title>
  <official_title>Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant ascites leads to significant morbidity in patients with terminal cancer.&#xD;
      Paracentesis can provide relief, but repeat hospital visits, pain, and short duration of&#xD;
      relief after paracentesis are detrimental to quality of life(QOL). Two devices are available&#xD;
      as alternatives to paracentesis. The impact of either device on QOL has not fully been&#xD;
      explored. A pilot nonrandomized trial measuring palliative care QOL and ascites symptom&#xD;
      relief using validated survey instruments is proposed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Industry funding not received. No subjects enrolled.&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Refractory Malignant Ascites</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Paracentesis</intervention_name>
    <description>Paracentesis</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tunneled Intraperitoneal Drain (IPD)</intervention_name>
    <description>Tunneled Intraperitoneal Drain (IPD)</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peritoneal-Venous shunts (PVS)</intervention_name>
    <description>Peritoneal-Venous shunts (PVS)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with refractory malignant ascites secondary to GU or GI malignancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Refractory malignant ascites defined as ascites requiring more than one paracentesis&#xD;
             to control patient symptoms despite medical therapy with diuretics and a. peritoneal&#xD;
             fluid with cytology positive for malignant cells OR&#xD;
&#xD;
          -  Known malignancy with imaging findings of peritoneal carcinomatosis .&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score 3&#xD;
&#xD;
          -  Age greater than or equal to 18&#xD;
&#xD;
          -  Capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy less than one month&#xD;
&#xD;
          -  Coagulopathy defined as international normalized ration (INR) &gt;2 which cannot be&#xD;
             corrected with fresh frozen plasma&#xD;
&#xD;
          -  Platelet count &lt;50,000/microliter, which cannot be corrected with platelet transfusion&#xD;
&#xD;
          -  Active skin infections at sites where PVS would be inserted&#xD;
&#xD;
          -  Presence of infectious peritonitis or bacteremia&#xD;
&#xD;
          -  Neutropenia&#xD;
&#xD;
          -  American Heart Association Class D congestive heart failure (ie New York Heart&#xD;
             Association Class IV)&#xD;
&#xD;
          -  Stage 5 CKD (ie GFR &lt; 15 mL/min)&#xD;
&#xD;
          -  Severe hypoalbuminemia defined as &lt; 2.2 g/dL&#xD;
&#xD;
          -  Loculated or hemorrhagic ascites&#xD;
&#xD;
          -  History of bleeding gastroesophageal varices&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Unable to participate in neuropsychological tests / questionnaires&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Anasarca&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Nadolski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult patients with refractory malignant ascites secondary to GU or GI malignancy.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

